A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2A by Colombo, Francesca et al.
RESEARCH Open Access
A5 ’-region polymorphism modulates promoter
activity of the tumor suppressor gene MFSD2A
Francesca Colombo
1†, Felicia S Falvella
1†, Antonella Galvan
1, Elisa Frullanti
1, Hideo Kunitoh
2, Toshikazu Ushijima
2
and Tommaso A Dragani
1*
Abstract
Background: The MFSD2A gene maps within a linkage disequilibrium block containing the MYCL1-EcoRI
polymorphism associated with prognosis and survival in lung cancer patients. Survival discrepancies between
Asians and Caucasians point to ethnic differences in allelic frequencies of the functional genetic variations.
Results: Analysis of three single-nucleotide polymorphisms (SNPs) mapping in the MFSD2A 5’-regulatory region
using a luciferase reporter system showed that SNP rs12072037, in linkage disequilibrium with the MYCL1-EcoRI
polymorphism and polymorphic in Asians but not in Caucasians, modulated transcriptional activity of the MFSD2A
promoter in cell lines expressing AHR and ARNT transcription factors, which potentially bind to the SNP site.
Conclusion: SNP rs12072037 modulates MFSD2A promoter activity and thus might affect MFSD2A levels in normal
lung and in lung tumors, representing a candidate ethnically specific genetic factor underlying the association
between the MYCL1 locus and lung cancer patients’ survival.
Background
A 106-kb linkage disequilibrium (LD) block on chromo-
some 1p34, which includes the TRIT1, MYCL1, and
MFSD2A genes, is associated with lung cancer prognosis
and survival [1], although conflicting results of the asso-
ciation of this region with prognosis, in particular of the
MYCL1-EcoRI polymorphism, have been reported [2,3].
Indeed, association of MYCL1-EcoRI with lung cancer
patients’ survival was observed in all of 4 studies of
Asians, but in none of 3 studies on Caucasians [3]. The
discrepancies might reflect ethnic differences in allelic
frequencies of the functional genetic variants mapping
in this locus, as suggested by the significant difference
between Caucasian and Asian subjects in the frequencies
of several SNPs located in the TRIT1, MYCL1, and
MFSD2A gene [1].
Modulation of expression of a gene mapping in the
MYCL1 region may represent a mechanism underlying
the association of this region with cancer patients’ survi-
val. Indeed, MYCL1 expression is not detected in
normal or tumor tissue. Both the TRIT1 and MFSD2A
genes are downregulated in lung adenocarcinomas
(ADCA), whereas overexpression of either gene has
tumor-suppressor effects [1,4,5]. The MFSD2A gene was
also strongly downregulated in a panel of non-small cell
lung cancer (NSCLC) cell lines, where it inhibits cell
adhesion and migration when overexpressed [5]. Thus,
available data suggest that downregulation of MFSD2A
plays a role in lung tumor progression.
Since functional polymorphisms in the promoter
region may affect mRNA levels of target genes by alter-
ing transcription factor (TF) binding sites [6,7], we ana-
lyzed three single-nucleotide polymorphisms (SNPs)
(rs3131703, rs12072037, and rs3738668) mapping in the
MFSD2A 5’ region for a potential role in altering
MFSD2A promoter activity.
Results
SNP rs3131703 in the MFSD2A 5’ regulatory region has
no functional effects on transcriptional activity
Among the MFSD2A 5’ region SNPs, only rs3131703,
located 1284 bp upstream of the start codon, has detect-
able allele frequencies in Caucasians. Genotyping of this
SNP in 151 Italian lung adenocarcinoma patients
revealed a minor allele frequency (MAF) = 0.46, i.e.,
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HapMap database for Caucasians (0.39, Table 1).
Analysis by quantitative real-time (qRT)-PCR to test
for an association between genotype and MFSD2A
mRNA levels revealed no significant difference between
two genotype groups of normal lung tissue samples
from 20 subjects in our series selected for homozygosity
at either allele (10 GG versus 10 AA samples) (data not
shown).
To study the functional role of rs3131703, a 1499-bp
fragment of the proximal promoter of the MFSD2A
gene containing either of the two alleles (G/A) was sub-
cloned into the pGL3-Basic vector upstream of the ATG
of the firefly luciferase gene (Figure 1A) and transfected
together with the Renilla luciferase pRL-TK reporter
vector into different cell lines (A549, Hek293T, HepG2,
HT-29, IGROV1, NCI-H520 and NCI-H596) for analysis
by Dual-Luciferase Reporter Assay. While the MFSD2A
promoter fragment containing SNP rs3131703 showed
functional transcriptional activity, since the normalized
firefly/Renilla luciferase activity was > 100-fold that of
the empty vector in Hek293T cells, the two allelic var-
iants of rs3131703 showed no statistically significant dif-
ferences in promoter activity in any of 7 cell lines
assayed, except for a weak effect of the G versus A allele
in Hek293T (1.1-fold higher activity; P = 0.011,
ANOVA) and NCI-H596 (1.1-fold increase, P = 0.007,
ANOVA) cells.
SNP rs12072037 is the major polymorphism involved in
modulation of MFSD2A promoter activity
The MFSD2A 5’ region rs12072037 (C/A alleles) and
rs3738668 (C/A alleles) SNPs, mapping at -759 bp and
-246 bp from ATG, respectively, are not polymorphic in
Caucasians, whereas in Asian populations, the frequen-
cies of the minor allele of these polymorphisms are
quite high (MAF = 0.47-0.48; Table 1). Accordingly,
sequencing analysis in a small number of Italian (n =
15) and Japanese (n = 15) lung cancer patients showed
that SNPs rs12072037 and rs3738668 defined two haplo-
types in Asians, AA and CC, whereas only the CC hap-
lotype was detected in Caucasians.
To study the functional role of rs12072037 and
rs3738668, we first tested the promoter activity of a
933-bp fragment of the MFSD2A gene proximal promo-
ter containing the two linked SNPs (AA and CC haplo-
types; Figure 1B) and subcloned into the pGL3-Basic
vector upstream of the ATG of the firefly luciferase
gene. Three of the 7 cancer cell lines transfected with
this construct showed a significant difference between
the two haplotypes in promoter activity. Indeed, HepG2,
HT-29, and IGROV1 cells showed 1.4-, 1.4-, and 1.2-
fold higher luciferase values, respectively, associated to
the AA haplotype (present in Asians) as compared to
the CC haplotype (the only one detected in our Italian
samples) (P < 1.0 × 10
-6 for each cell line, ANOVA; Fig-
ure 2). Both haplotypes showed functional promoter
activity, as indicated by the > 100-fold increase in luci-
ferase activity in Hek293T cells.
Similar analyses using a 699-bp fragment containing
only SNP rs3738668 (A and C alleles; Figure 1C)
revealed no overall modulation of MFSD2A promoter
activity, as indicated by luciferase values, except for a
marginally statistically significant effect only in Hek293T
cells (P = 0.022). As reported for the other constructs, a
> 100-fold increase in luciferase activity in Hek293T
cells was observed in the presence of either alleles of
rs3738668 SNP.
These findings point to SNP rs12072037 as the main
modulator of MFSD2A promoter activity.
SNP rs12072037 alleles create different putative
transcription factor binding sites
To determine whether SNP rs12072037 might modulate
MFSD2A promoter activity by altering putative tran-
scription factor (TF) binding sites in the MFSD2A 5’
region, we first predicted the potential differential TF
binding sites according to the presence of the A or C
allele of the polymorphism using MatInspector Release
professional 8.0[8]. In the presence of the A allele, bind-
ing sites for HLF (hepatic leukemia factor) and for the
AHR/ARNT (aryl hydrocarbon receptor/aryl hydrocar-
bon receptor nuclear translocator) heterodimer are gen-
erated (Figure 3A), whereas the same binding sites are
lost in the presence of the C allele, which instead leads
to a binding site for AR (androgen receptor) (Figure 3B).
qRT-PCR analysis of the four TFs potentially binding
at the SNP rs12072037 site in the cell lines revealed
Table 1 Allele frequency of the three validated SNPs in MFSD2A 5’ region by ethnicity
SNP Chromosome position
a Alleles
b Frequency of the minor frequency allele (MAF) in HapMap populations
a
Caucasians (CEU) Asians (JPT)
rs3131703 40192268 G/A 0.39 0.03
rs12072037 40192793 C/A 0.01 0.47
rs3738668 40193306 C/A 0.01 0.48
a Chromosome 1 position and allele frequencies extracted from the HapMap data (http://www.hapmap.org), accessed on August 17, 2010.
b Common/rare in
Caucasians.
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Page 2 of 7high-level expression of both AHR and ARNT in
HepG2, HT-29 and IGROV1 cells (Figure 4), in which
higher MFSD2A promoter activity in the presence of
the construct containing the A allele of rs12072037 was
also observed, whereas mRNA expression levels of the
two other TFs, i.e., AR and HLF in the different cell
lines showed no apparent correlation with MFSD2A
promoter activity (not shown).
To test the binding of AHR/ARNT heterodimer to the
construct containing the A allele, a preliminary
chromatin immunoprecipitation (ChIP) assay was car-
ried out using chromatin from cells transfected with
either of the two constructs. Real-time PCR analysis
revealed an approximately 2-fold increase of immuno-
precipitated DNA in the presence of the Asian allele
(not shown).
Discussion
We investigated the possible functional role of three
SNPs, located in the MFSD2A 5’-regulatory region
Figure 2 MFSD2A promoter activity modulated by genetic polymorphisms. Luciferase activity in cell lines transfected with recombinant
plasmids containing the MFSD2A 5’ region haplotypes (CC and AA) of SNPs rs12072037 and rs3738668, respectively. Data are mean ± S.E. of
normalized luciferase activity.
Figure 1 Recombinant vectors used to assay MFSD2A promoter activity. Schematic representation of recombinant vectors containing the
firefly luciferase reporter gene under the control of three MFSD2A 5’ region fragments of different length (panels A to C). Arrows indicate the
position of the three polymorphisms investigated (see Materials and Methods for details; UTR, untranslated region; luc+, firefly luciferase gene).
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modulating MFSD2A promoter activity. Luciferase
reporter assay indicated no such modulation by SNP
rs3131703, polymorphic only in the Caucasian popula-
tion, and MFSD2A mRNA levels in normal lung tissue
of lung cancer patients showed no statistically signifi-
cant association with rs3131703, thus excluding the
candidacy of this SNP as a functional genetic element
regulating MFSD2A promoter activity. By contrast,
analyses of SNPs rs12072037 and rs3738668, poly-
morphic in Asians, pointed to a functional role for
rs12072037 in modulating MFSD2A transcriptional
activity, showing allele-specific promoter activity in 3
of 7 cell lines.
Figure 3 In silico analysis of MFSD2A promoter binding sites. Schematic representation of the putative TF binding sites created by the
presence of the C (panel A) or A (panel B) allele of SNP rs12072037 in the MFSD2A 5’ region, predicted by MatInspector Release professional 8.0.
Sequences of the TF binding sites are shown, with alleles of rs12072037 shown in upper case. White boxes: 5’ region; dark-grey boxes: 5’-UTR;
light-grey boxes: coding region.
Figure 4 Cell line-specific expression of transcriptional factors putatively binding to the MFSD2A promoter. mRNA expression levels of
AHR and ARNT in the 7 cell lines tested for luciferase activity. Data are mean ± S.E. of logarithms of RQ values.
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profile [9], a SNP in a regulatory region could modulate
gene expression by altering TF binding sites, eliminating
the natural site or generating a novel one and thus alter-
ing binding strength [10].
To investigate the basis of the observed cell type-spe-
cific differential effects on transcriptional activity, we
measured expression of in silico-predicted TFs in the
cell lines used for promoter activity analysis. Transcrip-
tional levels of both AHR and ARNT were high in the
same three cell lines (HepG2, HT-29, and IGROV1)
showing higher MFSD2A promoter activity associated
with the A allele of rs12072037.
Accordingly, AHR and ARNT specifically bind to the
MFSD2A promoter containing the A allele of the
rs12072037 polymorphism. Moreover, NCI-H520 and
NCI-H596 cells, in which no modulation of MFSD2A
promoter activity by genetic polymorphisms was
detected, showed high levels of ARNT, but not of AHR,
suggesting that the AHR/ARNT heterodimer rather
than the single elements is necessary to increase
MFSD2A promoter activity, as reported for other target
genes [11]. Thus, the cell type-specific modulation of
reporter mRNA levels by the MFSD2A promoter might
be associated to the joint expression of AHR and
ARNT, which may form a dimer upregulating the
MFSD2A promoter variant containing the A allele at
rs12072037. Our preliminary ChIP experiment sup-
ported this hypothesis since differences in immunopreci-
pitated DNA levels were measured between the A and C
alleles of rs12072037. However, transfection of recombi-
nant plasmids in cancer cells where the endogenous
MFSD2A gene is strongly downregulated may not be
adequate to test the TFs modulating the natural
MFSD2A promoter in normal cells. To this aim, com-
parison of AHR and ARNT binding to the MFSD2A
promoter between normal cells carrying the different
rs12072037 genotypes would be required. Also, the
MFSD2A promoter fragment that we have transfected
contains an additional AHR/ARNT binding site down-
stream to the assayed site, causing a potential technical
bias in the ChIP assay. Therefore, we cannot exclude a
role for other TFs in affecting MFSD2A promoter
activity.
SNP rs12072037, which modulated MFSD2A tran-
scriptional activity, showed the most statistically signifi-
cant differences of allele frequencies between Caucasian
and Asian subjects among 12 SNPs mapping in the LD
block [1]; indeed, SNP rs12072037 is almost invariant in
Caucasians (Table 1). Furthermore, in Asians, the
rs12072037 functional promoter polymorphism shows a
significant LD with the MYCL1 SNP rs3134613 (EcoRI)
(D’ = 0.75, r^2 = 0.48, n = 88; genotypes of JPT samples
downloaded from HapMap, accessed on August 24,
2009; analysis carried out using the JLIN program [12]),
a SNP reported to be associated with prognostic factors
and survival of lung cancer patients in Asian patients
[3,13,14]. Together, these data suggest the candidacy of
rs12072037 as the functional variation in the MYCL1
locus responsible for modulating nodal status, metastasis
occurrence, and survival of lung cancer patients of Asian
ethnicity.
Conclusion
We identified SNP rs12072037 as the major polymorph-
ism modulating MFSD2A promoter activity. Further stu-
dies in Asian lung cancer patients are needed to test the
association of rs12072037 genotypes with MFSD2A
mRNA levels in normal lung tissue and to clarify the
role of this polymorphism in lung cancer progression
and prognosis.
Materials and Methods
Cell lines
Human lung cancer (A549, NCI-H520, NCI-H596),
hepatocellular carcinoma (HepG2), colorectal adenocar-
cinoma (HT-29), ovarian adenocarcinoma (IGROV1)
and embryonal kidney (Hek293T) cells were used. All
represent adherent epithelial cells. Each cell line was
propagated in the appropriate culture medium as
recommended by American Type Culture Collection,
except for IGROV1 cells, which were cultured in RPMI
1640 medium with 2 mM L-glutamine, 1.5 g/l sodium
bicarbonate, 10 mM HEPES, 1.0 mM sodium pyruvate,
4.5 g/l glucose and 10% FBS.
Search and genotyping of MFSD2A SNPs in 5’-region
Genomic DNAs were obtained from lung ADCA
patients (n = 151) enrolled at Istituto Nazionale Tumori,
Milan, Italy, and from lung cancer cases (n = 15) at the
National Cancer Center, Tokyo, Japan. Patients gave
written permission to use their biological material for
research purposes, and study protocols were approved
by the Institute committees for ethics.
SNP rs3131703 was genotyped in 151 Caucasian sam-
ples using pyrosequencing analysis on a PSQ96MA sys-
tem (Biotage AB, Uppsala, Sweden), according to the
manufacturer’s instructions using specific primers
reported in Additional file 1.
To identify haplotypes defined by SNPs rs12072037
and rs3738668, genomic DNAs of 15 Caucasian and 15
Asian lung cancer samples were PCR-amplified for 1160
bp spanning from the 5’- r e g i o nt oa ni n i t i a lp a r to f
intron 1-2 of MFSD2A using primer pairs reported in
Additional file 1. Sequences were determined using an
automatic sequencer (Applied Biosystems, Foster City,
CA) and aligned and compared using Genomatix Dia-
lign software (http://www.genomatix.de).
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Total RNAs were extracted with TRIZOL
® Plus RNA
Purification Kit (Invitrogen, Carlsbad, CA) from cell
lines and 20 normal lung tissue samples excised during
thoracic surgery for lung cancer at Istituto Nazionale
Tumori, Milan, Italy. Total RNAs were reverse-tran-
scribed using a 1:1 mix of oligo(dT)18 and random hex-
amer primers, according to the protocol recommended
for the Transcriptor First-Strand cDNA Synthesis Kit
(Roche). MFSD2A gene expression levels in lung sam-
ples were measured by qRT-PCR as described [5]. Tran-
scription factor mRNA levels in cell lines were assayed
by qRT-PCR using primer pairs listed in Additional file
1. Amplification mixtures contained cDNA template
diluted in RNase-free water, 12.5 μl2×P o w e rS Y B R
®
Green PCR Master Mix (Applied Biosystems) and 0.3
μM specific PCR primers in a final volume of 25 μl. The
human hypoxanthine phosphoribosyltransferase 1
(HPRT1) gene was used as housekeeping control. Reac-
tions were run in duplicate on the 7900HT System
(Applied Biosystems). Each experiment was repeated
three times. Relative changes in mRNA levels were
assessed using the comparative cycle threshold (Ct)
method, and relative quantities were calculated using
the A549 sample as calibrator.
Subcloning of MFSD2A 5’-region allelic variants into
luciferase reporter vector
Genomic DNAs of previously genotyped Caucasian indi-
viduals were selected for the two different alleles (G/A)
of rs3131703 (Figure 1A) to be amplified for the 5’ region
(1499 bp from ATG). Genomic DNAs of previously gen-
otyped Caucasian or Asian individuals were selected for
the CC or AA haplotype (rs12072037 and rs3738668),
respectively, to be amplified for 933 bp upstream of ATG
(Figure 1B). Finally, the shorter fragments (699 bp from
ATG), containing either of the two alleles (A/C) of
rs3738668 (Figure 1C), were PCR-amplified from the pre-
viously subcloned longer fragments (Figure 1B). PCR
amplifications were carried out using BIO-X-ACT Short
DNA Polymerase kit (Bioline, London, UK) and primer
pairs listed in Additional file 1. Fragments were cloned
into pGL3-Basic vector (Promega, Madison, WI)
upstream of the firefly luciferase reporter gene using
Rapid DNA Dephos & Ligation Kit (Roche, Basel, Swit-
zerland), according to the manufacturer’s instructions.
Luciferase reporter assays
Seven human cell lines derived from different tissues
were co-transfected with pGL3-Basic recombinant vec-
tors containing the different fragments of the MFSD2A
5’ region and the pRL-TK plasmid containing the
Renilla gene (Promega), using FuGene HD transfection
reagent (Roche) according to the manufacturer’s
instructions. Firefly luciferase was used as primary
reporter to monitor mRNA levels, whereas Renilla luci-
ferase served as control reporter for normalization. Cells
were assayed for luciferase activity 48 h after transfec-
tion using the Dual-Luciferase Reporter Assay System
kit (Promega), according to the manufacturer’si n s t r u c -
tions. Normalized signals were expressed as relative luci-
ferase units. Data from at least 6 replicas were evaluated.
Chromatin immunoprecipitation (ChIP) assay
HT-29 cells (2 × 10
6 cells/immunoprecipitation) were
transiently transfected with the pGL3-Basic recombinant
vectors containing the intermediate length fragment (Fig-
ure 1B) of the MFSD2A 5’ region and after 24 hours
crosslinking with 1% formaldehyde was carried out. Cell
lysis, micrococcal nuclease digestion of chromatin,
immunoprecipitation (IP) and DNA recovery were car-
ried out following the protocol of the Pierce Agarose
ChIP kit (Pierce, Thermo Scientific, Rockford, IL). IP was
carried out using anti-AHR and anti-ARNT transcription
factors (MA1-513 and PA3-16508 respectively, Thermo
Scientific) or normal rabbit IgG, as negative control.
Recovered and purified DNA was quantified with Nano-
drop Spectrophotometer ND-1000 (NanoDrop products,
Wilmington, DE, USA) and quantitative real-time PCR
was carried out with primers flanking the transcription
factor binding site (Additional File 1). DNA levels were
calculated by subtracting the Ct of the negative control
sample from the Ct of the immunoprecipitated sample,
to correct for the plasmidic DNA carry-over.
Statistical analyses
Associations of quantitative measurements with geno-
types or MFSD2A promoter variants were assessed by
analysis of variance, using the Rcmdr package in R [15].
Additional material
Additional file 1: List of primers used.
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